Litron Laboratories Ltd
Multiplexed DNA damage biomarker assay platform using flow cytometry for high-throughput genotoxicity testing
- Sector
- Biotech
- Headquarters
- Rochester, NY
- Total capital
- $11.3M
- Federal grants
- $10.9M
- 20 awards · 2015–2025
- Rank in peer group#18 of 32
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $426K
- 35 awards · Health and Human S, Defense
- Rank in Biotech#238 of 4373
- Granted patents
- 8
- 8 pending · first 2014
- Rank in peer group#3 of 32
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors$824K
- Federal contractHealth and Human S · Litron Multiflow And Microflow Kits$30K
- Federal grantHealth and Human S · Phase II · Development of a Comprehensive Hen's Egg Model for Genotoxicity Testing$1.2M
- Federal contractHealth and Human S · Litron Plus-r Invivo And Plus-rbm Invivo Microflow Kits (X3 Each)$24K
- Federal contractHealth and Human S · Pig-a Mutation Frequency Assays$98K
- Federal grantHealth and Human S · Phase II · Development of a Comprehensive Hen's Egg Model for Genotoxicity Testing$296K
- Federal contractHealth and Human S · Litron In-vitro Microflow Assay Kits, Qty 6$25K
Show 47 earlier federal awards
- Federal grantHealth and Human S · Phase I · Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors$230K
- Federal grantHealth and Human S · Phase II · High Throughput Screen and High Information Follow-Up Tests for Genotoxicants$683K
- Federal contractHealth and Human S · Microflow And Multi-flow In Vitro Kits$17K
- Federal grantHealth and Human S · Phase II · High Throughput Screen and High Information Follow-Up Tests for Genotoxicants$1.6M
- Federal grantHealth and Human S · Phase II · High Throughput Screen and High Information Follow-Up Tests for Genotoxicants$945K
- Federal contractHealth and Human S · Litron In Vitro Microflow Assay Kits$13K
- Federal grantHealth and Human S · Phase II · High Throughput Screen and High Information Follow-Up Tests for Genotoxicants$205K
- Federal grantHealth and Human S · Phase I · Development of rat liver 3D organoid methods to address genotoxicity screening$177K
- Federal grantHealth and Human S · Phase II · Next Generation Testing Strategies for Assessment of Genotoxicity$475K
- Federal contractDefense · Micronucleus Dna Study For Aphc, Aberdeen Proving Ground$44K
- Federal grantHealth and Human S · Phase II · Validation of Cross-Species Biomarkers of DNA Damage$617K
- Federal contractHealth and Human S · Microflow Assay Kits$23K
- Federal grantHealth and Human S · Phase II · Next Generation Testing Strategies for Assessment of Genotoxicity$482K
- Federal grantHealth and Human S · Phase II · Validation of Cross-Species Biomarkers of DNA Damage$629K
- Federal contractHealth and Human S · In Vitro Microflow Kits (micronucleus Analysis)$19K
- Federal grantHealth and Human S · Phase II · Next Generation Testing Strategies for Assessment of Genotoxicity$179K
- Federal grantHealth and Human S · Phase II · Validation of Cross-Species Biomarkers of DNA Damage$173K
- Federal grantHealth and Human S · Phase II · Automation of a Liver Genotoxicity Assay$510K
- Federal grantHealth and Human S · Phase II · Automation of a Liver Genotoxicity Assay$450K
- Federal grantHealth and Human S · Phase II · Automation of a Liver Genotoxicity Assay$173K
- Federal grantHealth and Human S · Phase II · Biomarker Matrix for Genotoxicity Mode of Action$484K
- Federal contractHealth and Human S · In Vitro Kit$5K
- Federal contractHealth and Human S · Igf Ot Igf Microflow In Vitro Kit$5K
- Federal contractHealth and Human S · In Vitro Kit$5K
- Federal grantHealth and Human S · Phase II · Biomarker Matrix for Genotoxicity Mode of Action$493K
- Federal contractHealth and Human S · Micronucelus Assay Kit$5K
- Federal contractHealth and Human S · In Vitro Micronucleus Assay Kit$5K
- Federal contractHealth and Human S · Igf::ot::igf Microflow Plus W/rat Blood&marrow$10K
- Federal contractHealth and Human S · Invitro Kits$9K
- Federal contractHealth and Human S · Invitro Kits$9K
- Federal contractHealth and Human S · Invitro Kit$5K
- Federal contractDefense · Plus-rbm$5K
- Federal contractHealth and Human S · Igf::ct::igf "critical Function" - Microflow ? In Vitro Kit: 2,000 Samples (96 Well Plateformat), Or 400 Samples (standard Format - I.e., Flasks Orplate Formats With Fewer Than 96 Wells).$5K
- Federal contractHealth and Human S · Micro Flow In Vitro Kits$5K
- Federal contractHealth and Human S · Microflow In Vitro Kit$5K
- Federal contractHealth and Human S · In Vitro Kit$5K
- Federal contractHealth and Human S · TAS::75 0600::TAS Microflow Kit For R Mittelstaedt Dial RKB-449 Litron$4K
- Federal contractHealth and Human S · TAS::75 0600::TAS In Vitro Kits$4K
- Federal contractHealth and Human S · TAS::75 0600::TAS In Vitro Test Kit$5K
- Federal contractHealth and Human S · Litron Labs - John Cookplus-m Micro Flow Plus Kit - 5 Each$10K
- Federal contractDefense · Microflow Rat Micronucleus Plus Kit$6K
- Federal contractHealth and Human S · Ntp E02141 11 Heflich Mcgarrity LJM-108 Litron 1506 00 Prism$2K
- Federal contractDefense · Microflow Rat Micronucleus Plus Kit$6K
- Federal contractDefense · Microflow Rat Micronucleus Plus Kit$4K
- Federal contractDefense · Microflow Rat Micronucleus Plus Kit$6K
- Federal contractDefense · Microflow In Vitro Kit$2K
- Federal contractHealth and Human S · Ntp E2141 Heflich For Micronucleus Kits$6K
Federal awards are summed by year (54 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 32 peers
Line = medianBiotech · Instrument
- Federal grantsBelow median
- Granted patents#3 · top 9%
- Linked publications#1 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 8 granted of 16- GrantedSimplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsUSPTOUS 11,828,763
- GrantedSimplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsUSPTOUS 11,016,101
- GrantedSimplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsUSPTOUS 10,802,013
Show all 16 patent records
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsNov 28, 2023 · US 11,828,763Granted
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsMay 25, 2021 · US 11,016,101Granted
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsOct 13, 2020 · US 10,802,013Granted
- Method For Enumeration Of Mammalian Cell Micronuclei, While Distinguishing Chromatin Of Dead And Dying CellsJun 19, 2018 · US 10,000,793Granted
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsJan 2, 2018 · US 9,857,358Granted
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsOct 18, 2016 · US 9,470,694Granted
- Method For The Enumeration Of Mammalian Micronucleated Erythrocyte Populations, While Distinguishing Platelets And/or Platelet-associated AggregatesMar 15, 2016 · US 9,285,365Granted
- Method For The Enumeration Of Mammalian Micronucleated Erythrocyte Populations, While Distinguishing Platelets And/or Platelet-associated AggregatesNov 18, 2014 · US 8,889,369Granted
- Method For Enumerating Eukaryotic Cell Micronuclei With An Emphasis On Simultaneously Acquiring Cytotoxicity And Mode Of Action InformationJan 16, 2014 · Application 13791912Pending
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsApplication 61775494Pending
- Simplified Nuclei Analysis Platform And Biomarker Matrix That Supports Genotoxic Mode Of Action DeterminationsApplication PCTUS2014021837Pending
- Rapid In Vivo Gene Mutation Assay Based On The Pig-a GeneApplication PCTUS2011062125Pending
- Quantitative Analysis Of In Vivo Mutation At The Pig-a LocusApplication PCTUS2009047201Pending
- Method For Measuring In Vivo Hematotoxicity With An Emphasis On Radiation Exposure AssessmentApplication PCTUS2008066978Pending
- Method For Enumerating Mammalian Cell Micronuclei With An Emphasis On Differentially Staining Micronuclei And The Chromatin Of Dead And Dying CellsApplication PCTUS2005022448Pending
- Method For The Enumeration Of Micronucleated Erythrocyte Populations While Distinguishing Platelets And/or Platelet-associated AggregatesApplication PCTUS2004020647Pending
Recent research by its founders
- Abstract 3148: Human blood micronucleated reticulocytes: Application as a pharmacodynamic biomarker for DNA double strand breaks in oncology drug development20260 cites
- INVESTIGATION OF ETHYLENE OXIDE GENOTOXICITY DOSE-RESPONSE TO INFORM CANCER RISK ASSESSMENT20260 cites
- Sex and Alkyladenine DNA Glycosylase Expression are Key Susceptibility Factors for NDMA-induced Mutations, Toxicity, and Cancer20253 cites
Related companies, and why
- APPLIED BIOTECHNOLOGY INSTITUTESimilar federal contract value in Biotech · $450K in contracts
- Nanode Therapeutics, Inc.Similar federal contract value in Biotech · $441K in contracts
- Rejuvenics Technologies LLCSimilar federal contract value in Biotech · $438K in contracts
- Cell Surgical Network CorporationSimilar federal contract value in Biotech · $413K in contracts
- ExelixisSimilar federal contract value in Biotech · $401K in contracts
- Stemgent, Inc.Similar federal contract value in Biotech · $400K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .